Home › Research › Tau biomarkers
Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Their Role in Clinical Chemistry
Kaj Blennow, Douglas Galasko. EJIFCC, 2000-03-21
Topic: Plasma and spinal-fluid biomarkers
Plain-language summary
In view of current (AChE inhibitors) and future (e.g. anti-Aβ aggregators), development and evaluation of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) has become a rapidly growing research field. Diagnostic biomarkers for AD would be especially valuable as aids in the diagnosis early in the course of the disease, when correct diagnosis is difficult, and when therapeutic compounds have the greatest potential of being effective. This paper reviews CSF biomarkers for AD, with emphasis on their role in the clinical diagnosis, and methodological aspects of importance for developing such analyses. Today, two biochemical markers, CSF-tau and CSF-Aβ42, perform satisfactory enough to have a role in the clinical workup of patients dementia, if used together with the cumulative information from clinical information and brain-imaging techniques. These markers are especially useful to discriminate early or incipient AD from age-associated memory impairment, depression, and some secondary dementias.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Blennow, K., & Galasko, D. (2000). Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Their Role in Clinical Chemistry. EJIFCC.
Vancouver
Blennow K, Galasko D. Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Their Role in Clinical Chemistry. EJIFCC. 2000. PMID: 30675139.
BibTeX
@article{blennow2000-30675139,
author = {Blennow, Kaj and Galasko, Douglas},
title = {{Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Their Role in Clinical Chemistry}},
journal = {EJIFCC},
year = {2000},
pmid = {30675139}
}
Built from the record alzhub holds for this paper, not looked up. This record has no DOI, so the citation leaves it out. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- In view of current (AChE inhibitors) and future (e.g. anti-Aβ aggregators), development and evaluation of cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease (AD) has become a rapidly growing research field.
- Diagnostic biomarkers for AD would be especially valuable as aids in the diagnosis early in the course of the disease, when correct diagnosis is difficult, and when therapeutic compounds have the greatest potential of being effective.
- This paper reviews CSF biomarkers for AD, with emphasis on their role in the clinical diagnosis, and methodological aspects of importance for developing such analyses.
- Today, two biochemical markers, CSF-tau and CSF-Aβ42, perform satisfactory enough to have a role in the clinical workup of patients dementia, if used together with the cumulative information from clinical information and brain-imaging techniques.
- These markers are especially useful to discriminate early or incipient AD from age-associated memory impairment, depression, and some secondary dementias.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Evidence strengthLow
How this study scored 38/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 21 of the 56 points we could judge it on, which is 38 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (EJIFCC) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2000 — older than 20 years, still counted |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30675139) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 21 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 21 of the 56 points we could judge it on is 38 out of 100. |
| Total | 38 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Tau biomarkers from nearby years
Also tagged “p-tau217”
692 studies in the library carry the topic tag “p-tau217”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 692 tagged studies.